- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (mnc pharma)
- GSK PHARMA
GSK PHARMA Share Price 
(GLXO)
Here is the latest stock price and chart of GSK Pharma. For more details, see the GSK Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Oct 15, 2018 02:29:00 PM | ||
|---|---|---|---|
| Price (Rs)1,421.20 | Open (Rs) 1,419.00 | High (Rs) 1,438.00 | Low (Rs) 1,398.10 |
| % Change1.20 | Volume 1,869 | Value (Rs) 2,656,223 | 52-Week H/L 1,812.00 / 1,020.00 |
| Live NSE Quotes | Oct 15, 2018 2:34:58 PM | ||
|---|---|---|---|
| Price (Rs)1,427.95 | Open (Rs) 1,439.70 | High (Rs) 1,439.70 | Low (Rs) 1,395.05 |
| % Change1.48 | Volume 13,426 | Value (Rs) 19,124,800 | 52-Week H/L 1,800.05 / 1,010.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 24.45 | P/E Ratio (x) 58.13 | Market Cap (Rs m) 240,759.81 | P/BV (x) 11.70 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
GSK PHARMA Share Price Today:
GSK PHARMA share price is up 1.2% to Rs 1,421.2 on the BSE. On the NSE, the GSK PHARMA share price is up 1.5% to Rs 1,428.0. The total volume of shares traded is 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading up by 1.6%. And the benchmark S&P BSE SENSEX is at 34,705.6 (down 0.1%).
Over the last 30 days, the GSK PHARMA share price is down 17.6%. And over the last one year, GSK PHARMA share price is up 17.1%.
|
| |
Today's Market
Sensex Trades Flat; Pharma Stocks Lead Gains(12:30 pm)
After opening the day in green, share markets in India have traded on a volatile note and are presently trading below the dotted line.
Related Views On News
GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)
Jul 26, 2018 | Updated on Jul 26, 2018For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)
May 28, 2018 | Updated on May 28, 2018For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)
Oct 5, 2018Find companies with long term durable moats, which are correcting with the current broader market sell-off.
Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)
Oct 4, 2018Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.
Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)
Oct 5, 2018Ajit Dayal on the crisis in the market and in the mutual fund industry.
Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)
Oct 3, 2018A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.
Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)
Oct 3, 2018Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.
MoreTRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA - TEVA PHARMA COMPARISON
COMPARE GSK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.